A Common Antidepressant Medication Eases Long COVID’s Crushing Fatigue

Vidcast:  https://www.instagram.com/p/DblrZZ2h8r0/Collaborators at the Brazilian Biomedical Research Institute, Canada’s McMaster University, and Stanford tested fluvoxamine, also known as Luvox, in 399 adults whose fatigue had persisted for at least 90 days after COVID. Participants separated into 3 groups received either fluvoxamine, the diabetes drug metformin, or placebo for 60 days. Fluvoxamine produced a statistically significant improvement. At 60 days, fatigue scores were 0.43 points lower than placebo, with the benefit increasing to 0.58 points at 90 days. Participants taking fluvoxamine also reported improvements in quality of life.  Metformin did not improve established long COVID fatigue in this trial.These findings are promising, but the improvement was relatively modest. Confirmation and additional studies will be needed to see if these results can be repeated and even improved. Currently, fluvoxamine is not yet an established or an FDA approved treatment for long CoVid. It may be someday.References on my website.#LongCOVID #Fluvoxamine #COVID19 #MedicalResearch #ChronicFatigue